Dexamethasone in community-acquired pneumonia.

Phase 4

Completed

• Conditions: Pneumonia; respiratory tract infection; 10024970

• Registration Number: NL-OMON43565
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 600

Inclusion Criteria

Patients aged 18 to 100 years with a community-acquired pneumonia which requires admission.
Criteria to determine a community-acquired pneumonia:
- Chest radiograph showing new opacities.
In combination with two of the following findings:
0 Cough
0 Production of sputum
0 Temp >38,0 °C or <36,0 °C
0 Audible abnormalities by chest examination compatible with pneumonia
0 Leukocytosis (>10.000 cells/mm3), leftward shift (>10%) or leucopenia (<4000 cells/mm3)
0 CRP >15 mg/l (three fold higher than the upper limit of normal)

Exclusion Criteria

- Immunocompromised patients:
0 Patients with a known congenital or acquired immunodeficiency.
0 Patients who received chemotherapy less than 6 weeks ago.
0 Patients who received corticosteroids in the last 6 weeks.
0 Patients who received immunosuppressive medication in the last 6 weeks (e.g. cyclosporin, cyclophosphamide, azathioprine).
0 Patients with COPD who are on systemic corticosteroids for COPD.
- Patients who require ICU treatment.
- Patients with tropical worm infection.
- Patients with dexamethasone intolerance.
- Pregnant and breastfeeding women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Length of hospital stay.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- 30-day mortality;<br /><br>- Admission to ICU after initial admission on the ward.</p><br>